Pre-exposure chemoprophylaxis for HIV: it is time.
The HIV-1 plague continues unabatedly across sub-Saharan Africa. In Botswana and Swaziland, nearly 40% of the entire adult population is already infected. No current program is capable of slowing the advancing tide. An effective vaccine and widespread treatment are years, if not, decades away. In this most urgent situation, I propose that pre-exposure chemoprophylaxis be studied as a means to reduce the spread of HIV-1 among at-risk individuals.
Smith
Stephen M
SM
Saint Michael's Medical Center and The New Jersey Medical School, Newark, New Jersey 07102, USA. ssmith1824@aol.com
D000163:Acquired Immunodeficiency Syndrome / Q000453:epidemiology / Q000517:prevention & control; D017954:Africa South of the Sahara / Q000453:epidemiology; D019380:Anti-HIV Agents / Q000494:pharmacology*; D018890:Chemoprevention / Q000379:methods*; D003906:Developing Countries / Q000706:statistics & numerical data; D004345:Drug Industry; D015658:HIV Infections / Q000453:epidemiology / Q000517:prevention & control; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D015994:Incidence
D019380:Anti-HIV Agents